Portfolio Analysis in Brussels.

A patent portfolio analysis Brussels in-house teams can put in front of a board has to speak two languages at once — the science of the estate and the regulatory strategy that sits on top of it. Brussels is the capital of the European Union, the seat of the Commission and the Council, and the place where medicines policy, supplementary protection certificates and the coming unitary SPC are actually decided. That makes a Belgian portfolio unusually policy-exposed: its value turns not only on the patents themselves but on the exclusivity layers stacked around them. PerspireIP builds portfolio studies for the R&D leaders and IP counsel running estates out of Brussels, Wallonia and the Leuven deep-tech corridor.

The work is landscape, gap, strength and valuation analysis — not litigation. It is the diligence that supports a pharma licensing deal, the schedule that lets a VIB or imec spin-out show real IP to a growth investor, and the maintenance-fee decision that keeps a Belgian estate from quietly overspending across the European Patent Office and its validation states.

Why patent portfolio analysis Brussels teams start with the EU regulatory map

In most cities a portfolio review starts with the technology. In Brussels it starts with the policy that governs the technology. This is the EU’s regulatory capital: the European Commission, the Council and the lobbying and trade-association ecosystem around them shape patent term, data exclusivity, supplementary protection and the pharmaceutical legislation review that is redrawing all of it. A portfolio owned or managed from Brussels lives inside that debate, and its value moves with it.

That framing changes what a study has to deliver. A landscape map here is not just a claims chart — it is a read on where a competitor’s exclusivity actually ends once you account for the patent, any SPC and any regulatory protection stacked on the same product. We build patent portfolio analysis Brussels licensing teams, investment committees and general counsel can act on, tied to the deal, the launch or the budget cycle that prompted it.

• Licensing and M&A diligence — validity, ownership chain, encumbrances and product coverage before a bid or a deal
• Venture and growth financing — an honest read of whether the IP backs a spin-out’s story to a Series A/B investor
• Exclusivity mapping — patent term plus SPC plus regulatory data protection, read as one timeline
• Board and budget reviews — a periodic strength, gap and annuity picture for the CFO and the general counsel

SPCs, the coming unitary SPC and Belgian pharma and vaccine estates

Belgium’s patent economy is built on medicines. GSK runs one of the world’s largest vaccine operations from Wavre and Rixensart — Wavre is its global vaccines manufacturing hub and the division headquarters, Rixensart its historic vaccine R&D centre. UCB has invested around a billion euros in its Braine-l’Alleud biologics and gene-therapy campus, and Solvay anchors a deep chemicals estate. These portfolios do not end at the patent claim; their commercial life is extended by supplementary protection certificates.

An SPC extends the effective term of a patent covering an authorised medicinal or plant-protection product by up to five years, compensating for the time lost to marketing authorisation. For a pharma or vaccine estate, the SPC is frequently the single most valuable asset attached to a molecule, and mis-managing its filing deadlines or scope can strip years of exclusivity. Any serious Belgian portfolio review has to price the SPC alongside the patent, not as an afterthought.

That picture is about to change. The EU is finalising a centralised examination procedure for SPCs and a genuine unitary SPC that pairs with the unitary patent, so that one application yields protection across participating member states rather than a separate national certificate in each. For a portfolio owner this is both an opportunity and a migration question: which future products should ride the unitary route, and how do existing national SPCs across the validation states fit the new system? We map that transition asset by asset.

OPRI/DIE and how Belgian patents are actually granted

National filings in Belgium go to the Belgian Office for Intellectual Property — OPRI in French, DIE in Dutch — a directorate of the Federal Public Service (FPS) Economy based in Brussels. It is a registration office, not an examining one: Belgium grants patents without substantive examination of patentability. The European Patent Office prepares a search report on the prior art, but the outcome does not affect the grant, and there is no post-grant opposition procedure at OPRI.

That matters enormously for portfolio strength. A granted Belgian national patent carries no presumption that it was examined on the merits, so its real validity is an open question until someone tests it against the search report and the wider art. A portfolio built on unexamined national grants can look larger than it is; grading each asset against the prior art is how you tell the difference between a right that will hold and one that is a paper tiger.

Most commercially important Belgian coverage today arrives through the European route instead. Belgium is an EU member, a Unified Patent Court state and a party to the London Agreement, so a granted European patent needs no Belgian translation to take effect, and a unitary patent covers Belgium automatically. Belgium has also closed its direct national PCT route — international applications reach Belgium only as Euro-PCT filings through the EPO. A portfolio study has to know, for every asset, which of these routes produced it and what that implies for term, cost and enforceability.

imec, KU Leuven and Belgium’s deep-tech university IP

Twenty minutes from Brussels sits one of Europe’s densest deep-tech IP clusters. imec, the Leuven-based nanoelectronics and digital-technology research institute, is a world leader in advanced semiconductor R&D and generates a stream of patents and licences across chips, sensors and photonics. KU Leuven is one of Europe’s most active patent-filing universities, its LRD tech-transfer office spinning inventions out to industry, and VIB adds a powerful life-sciences patent estate on top.

University and institute portfolios behave differently from a corporate estate. The value is concentrated in early-stage, broadly drafted families whose commercial fate depends on licensing, spin-out formation and the strength of the priority filings rather than on covering a shipping product. For a spin-out raising capital, the diligence question is whether the IP was cleanly assigned out of the university, whether the family still has runway on its priority dates, and whether the claims read on the intended product.

• Spin-out and licensing diligence — clean chain of title from imec, KU Leuven or VIB to the operating company
• Family and priority audit — how much term and geographic reach the founding filings really have
• Coverage mapping — whether the claims cover the deep-tech or biotech product the company is actually building
• Freedom-to-operate context — who else holds patents in the same nanoelectronics or biologics space

The stakes are commercial. imec alone operates on a research budget of hundreds of millions of euros and partners with the whole global semiconductor industry, so its licensable patents sit in one of the most contested technology spaces on earth. A founder or investor who treats that IP as a checkbox rather than reading its real depth is exposed; a disciplined portfolio study turns the family into an asset a growth investor can underwrite with confidence.

The Brussels Enterprise Court and the UPC Local Division

Portfolio risk is partly forum risk, so a Belgian owner should know where its patents would be litigated. National patent disputes in Belgium are concentrated in a single venue: the Brussels Enterprise Court (Tribunal de l’entreprise / Ondernemingsrechtbank), which holds exclusive national jurisdiction over patent matters. Proceedings run in French or Dutch, and choosing between the French-language and Dutch-language chambers is itself a strategic decision that a portfolio’s risk map should anticipate.

Alongside the national court, a Unified Patent Court Local Division now sits in Brussels, hosted on the premises of the FPS Economy to give Belgian businesses local access to the new pan-European system. For the Belgian part of a European patent that has not been opted out, a dispute can go either to the Brussels Enterprise Court or to the UPC; for a unitary patent, the UPC is exclusively competent. Local divisions hear infringement, while revocation is centralised.

That split is a portfolio decision, not just a litigation one. Every unopted-out European patent in a Belgian estate is now exposed to a single central UPC revocation that can knock it out across all member states at once, while an opt-out keeps it in the national lane. We flag which assets are opted out, which are exposed, and where a Belgian-anchored assertion — national or UPC — is realistic, so the estate can be strengthened or pruned before a dispute rather than during one.

Landscape, gap and valuation across a Belgian estate

The offensive side of portfolio work is finding what you do not yet own. A landscape maps the patents held by you and your competitors across a technology area; a gap or white-space analysis then shows where protectable, commercially useful inventions sit unclaimed — the space your R&D leaders should be filing into before a rival does. For a Brussels pharma or deep-tech owner, a patent portfolio analysis Brussels teams trust has to read that map at European scale, because the competition and the case law are pan-EU.

Valuation is where the Belgian regulatory layer bites hardest. Pricing a medicinal estate means modelling the patent term, any SPC extension and the data and market exclusivity from the marketing authorisation as one combined exclusivity runway — the number that a licensee, an acquirer or a lender actually cares about. A deep-tech estate is valued differently again, on licensing potential and standards exposure rather than a single blockbuster molecule.

• Competitive landscape maps — who holds what across your technology space, by assignee, claim scope and filing trend
• Gap and white-space analysis — unclaimed, protectable ground to direct the next filing program
• Exclusivity-runway valuation — patent, SPC and regulatory protection modelled as one combined timeline
• Strength and coverage scoring — how well the estate actually covers the products and the roadmap

Because Belgium sits at the centre of the EU single market, a landscape drawn only around Belgian filings will miss most of the field. Competitors protect the same products through European and unitary patents that reach Belgium without ever appearing in a purely national search, and the case law that will decide claim scope is now written by the Unified Patent Court and the EPO Boards of Appeal, not by a single national bench. We therefore run the landscape at European scale and then localise it — showing which competitors have validated in Belgium, which have taken unitary effect, and where the white space is genuinely open for a Belgian owner to file.

How PerspireIP builds a portfolio analysis you can act on

Every engagement follows the same disciplined path, scaled to whether you are prepping a data room, defending a budget or planning next year’s filings. We inventory the portfolio, verify legal status and ownership across the EPO and Belgian records, map each asset and its SPCs to products and competitors, grade strength and UPC exposure, and price the estate for the transaction or decision that prompted the review.

• Full inventory with legal-status, term and renewal timeline for every patent and SPC
• Product-to-patent coverage mapping and a claim-strength score across the estate
• SPC and regulatory-exclusivity runway modelled alongside the underlying patents
• UPC opt-out and central-revocation exposure flagged asset by asset
• Landscape, gap and white-space maps at European scale, with clean chain-of-title checks for university and spin-out IP
• A valuation view for licensing, M&A or financing, delivered as data-room-ready exhibits

We work alongside your in-house IP team, licensing group or outside counsel as a specialist analysis partner, deliver to your deal or budget calendar, and keep every engagement confidential. Whether you need a one-time diligence study before a Brussels licensing deal, an annual portfolio health check for the board, or an ongoing pruning and landscaping program, we scale to fit. Send us the assignee name or a patent list and we will scope a patent portfolio analysis Brussels project within one business day.

IP Landscape & Resources in Brussels

Key intellectual-property authorities and venues relevant to Brussels:

• Belgian Office for Intellectual Property (OPRI/DIE), FPS Economy — the Brussels registration office that grants Belgian patents without substantive examination and records SPCs, a core status source for any Belgian portfolio audit
• Unified Patent Court — the pan-European court whose Brussels Local Division hears infringement and whose central division can revoke a European patent across all member states at once
• European Patent Office (EPO) — grants the European and unitary patents that make up most Belgian coverage and prepares the search report behind unexamined Belgian national grants
• World Intellectual Property Organization (WIPO) — PATENTSCOPE — global patent-family and publication data used for landscape, gap and white-space analysis across jurisdictions

Request a Patent Portfolio Analysis in Brussels

Explore related PerspireIP services: Patent Portfolio Analysis services · IP services in Belgium · patent invalidation · prior art litigation search · patent infringement analysis · patent market research.

Frequently Asked Questions